Cardiomyopathies - NYSORA

Explore NYSORA knowledge base for free:

Cardiomyopathies

Learning objectives

  • Recognize the different classes of cardiomyopathies
  • Anesthetic management of patients with cardiomyopathy

Definition & mechanisms

  • Cardiomyopathy is myocardial disorder in which the heart muscle is structurally and functionally abnormal 
  • Can be inherited or acquired 
  • Can affect all age groups
  • Affects the shape, function, and electrical system of the heart. 
  • Signs and symptoms can usually be managed successfully and patients can have a good life expectancy

Dilated cardiomyopathy

  • Dilatation of the left and right ventricles, impaired systolic function 
  • Major cause of heart failure and arrhythmia in young adults
  • Two-thirds of cases are idiopathic
  • Possible causes:
    • Familial association
    • Post-viral infection
    • Part of a disease process (ischemic heart disease, hypertension, diabetes, malformation syndrome, alcohol excess, neuromuscular disorder, inborn errors of metabolism, exposure to cardiotoxic agents)
  • Asymptomatic in early stages
  • Symptoms of heart failure (dyspnea, fatigue, ascites, peripheral edema, arrhythmias)
  • Embolic events and sudden death may occur at a later stage
  • Diagnosis: Echocardiography, chest radiograph, electrocardiography, blood tests, detailed medical and family history, physical examination

Management

dilated cardiomyopathy, management, heart failure, arrhythmia, echocardiography, myocardial depression, preload, afterload, tachycardia, hypotension, peripheral nerve blocks, neuraxial anesthesia, etomidate, ketamine, propofol, volatile anesthetic agents, opioids, arterial and venous catheters, transesophageal echocardiography, toe, bis, inotropic, phosphodiesterase inhibitors, levosimendan, dobutamine, dopamine, noradrenaline, biventricular pacing, intra-aortic balloon pump, icu, analgesia

SVR, systemic vascular resistance; BIS, bispectral index; ICU, intensive care unit

Hypertrophic cardiomyopathy

  • Hypertrophy of the left ventricle in the absence of other structural or functional abnormalities
  • Inherited disease of the myocardium
  • Hypertrophy can be asymmetrical, concentric, midventricular, apical, and can also involve the right ventricle
  • Diastolic impairment of the left ventricle
  • End-stage: Biventricular systolic dysfunction due to myocardial fibrosis
  • 70% of cases have obstructive hypertrophy
  • Majority of patients is asymptomatic
  • Symptoms of angina and heart failure (dyspnea, chest pain, syncope, arrhythmia)
  • Severe complications: Angina pectoris, heart failure, sudden death 

Management

hypertrophic cardiomyopathy, hcm, fluid, preload, afterload, management, svr, sympathetic, contractility, tachycardia, sinus rhythm, hypotension, iv fluis bolus, phenylephrine, LVOTO, invasive monitoring, transesophageal echocardiography, inotropes, pulmonary capillary wedge pressure, regional anesthesia, spinal, icu, analgesia

SVR, systemic vascular resistance; LVOTO, left ventricular outflow tract obstruction

Restrictive cardiomyopathy

  • Impairment of ventricular diastolic function due to fibrotic or infiltrative changes in the myocardium and/or subendocardium
  • Primary or secondary (amyloidosis, sarcoidosis, hemochromatosis, ischemic heart disease, hypertension, valvular disease)
  • Symptoms of biventricular failure (dyspnoea, orthopnea, fatigue, palpitation, edema, chest pain)
  • On physical examination, patients may have an audible third heart sound, systolic murmur, raised jugular venous pressure, ascites, and peripheral edema
  • Diagnosis: Echocardiography, endomyocardial biopsy, computed tomography, cardiac MRI

Management

  • General anesthesia causes vasodilation, suppresses the myocardium, and reduces venous return. The latter can be exacerbated by intermittent positive ventilation resulting in cardiac arrest. 
  • Invasive arterial blood pressure monitoring and transesophageal echocardiography are useful in identifying the causes of cardiovascular instability.
  • Hemodynamic goals: 
    • Maintain adequate preload, SVR, and sinus rhythm
    • Use an anesthetic agent with minimal cardiovascular effect (ketamine or etomidate)

Arrhythmogenic right ventricle cardiomyopathy

  • Structural abnormalities and cardiac dysfunction of the right ventricle, can also involve left ventricle
  • Complex genetic condition
  • Other causes: Degenerative disease, infection, inflammation 
  • Usually starts as a localized disease with regional wall abnormalities
  • Development of right bundle branch block followed by right ventricular failure between the fourth and fifth decades of life
  • Young patients often present with arrhythmia, syncope, cardiac arrest, or sudden death
  • 3 clinical phases:
    • Phase 1 (concealed disease): Some structural abnormality in the myocardium, patients can present with sudden cardiac death
    • Phase 2 (overt disease): Established structural abnormality of the myocardium, patients present with arrhythmias and syncope
    • Phase 3 (End-stage disease): Severe structural changes

Management

  • Arrhythmias of both supraventricular and ventricular may occur at any time
  • Avoid hypovolemia, hypercarbia, acidosis and lighter depth of anesthesia 
  • Amiodarone is the first line of medication to treat rhythm disturbances
  • Placement of implantable cardioverter defibrillator is beneficial

Suggested reading

  • Ibrahim IR, Sharma V. Cardiomyopathy and anaesthesia. BJA Education. 2017;17(11):363-9.

We would love to hear from you. If you should detect any errors, email us customerservice@nysora.com